The Future of Plaque Psoriasis Therapy
Expert dermatologists highlight the future of plaque psoriasis treatment, commenting on advances in therapy as well as increasing access to treatment.
Using IL-23 Inhibitors in Clinical Practice for Plaque Psoriasis
Benjamin Lockshin, MD, FAAD; and Jennifer Soung, MD, share their experience with IL-23 inhibitors for the treatment of plaque psoriasis in clinical practice.
Selecting IL-23 Inhibitors for Treating Plaque Psoriasis
Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis.
Shifting the Paradigm for Plaque Psoriasis Therapy
Expert dermatologists discuss the paradigm shift occurring in the management of plaque psoriasis as a result of the expanded array of treatment options.
Head-to-Head Studies for Plaque Psoriasis Therapies
Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.
Considering Safety of IL-23 Inhibitors for Plaque Psoriasis With The Patient
Expert dermatologist comments on initiating conversations about the safety of IL-23 inhibitors with patients with plaque psoriasis, highlighting biologic-naive patients.
Efficacy of IL-23 Inhibitors for Plaque Psoriasis
Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment.
Approaches to Treating Plaque Psoriasis
Expert dermatologists share how the understanding of the pathophysiology of plaque psoriasis guides approaches to therapy.
Impact of Plaque Psoriasis on Quality of Life
Drs Bruce Strober, Benjamin Lockshin, and Jennifer Soung discuss how plaque psoriasis impacts a patient’s quality of life, focusing on patient-reported outcome measurements as well as special areas affected by plaque psoriasis.
Future Directions in the Use of TYK2 Inhibitors for the Treatment of Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, review the clinical and practical impact of TYK2 inhibition and its evolving role within the treatment landscape for psoriatic disease.
Potential Uses for TYK2 Inhibitor Regiments in Plaque Psoriasis and Psoriatic Arthritis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the potential use of TYK2 inhibitors in combination with other modalities.
Navigating Treatment Access Challenges in Patients With Plaque Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, share considerations for ensuring that patients on Medicare and Medicaid receive the appropriate medication.
Expert Insights on Therapeutic Selection for the Treatment of Plaque Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the nuances of treatment selection for patients with moderate to severe plaque psoriasis.
Laboratory Evaluations for TYK2 Inhibitors in the Treatment of Psoriasis
Thought leaders talk about blood monitoring protocols with deucravacitinib.
Reviewing the Safety Profile of Deucravacitnib
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, place the safety data for deucravacitinib in clinical context.
Evaluating Clinical Trial Data for Deucravacitinib in Plaque Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, explore the phase 3 data for deucravacitinib, as well as the dosage, and lack of drug-drug interactions associated with it.
Understanding the Differences Between Inhibiting TYK2 Versus Traditional JAK Inhibition
Thought leaders talk about the approval and integration of a first-in-class agent into the treatment armamentarium. They also review the mechanisms of TYK2 inhibition.
Psoriasis Treatment Landscape Overview and Assessment of Efficacy
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, assess the efficacy of traditional and newer treatment options for psoriasis. They also discuss therapeutic targets and the goals of therapy.
2 Clarke Drive Cranbury, NJ 08512